Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. (CLDI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cldi · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Calidi Biotherapeutics, Inc. (CLDI) measures how much investors pay for each dollar of the company's trailing earnings. CLDI's current PE ratio of N/A is calculated by dividing its stock price of $0.17 by its TTM earnings per share of -$1.85.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Calidi Biotherapeutics, Inc.You CLDI | $1M | N/A | — | -$1.85 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Kazia Therapeutics Limited KZIA | $18M | N/A | — | -$18.90 |
 Qualigen Therapeutics, Inc. QLGN | $5M | N/A | — | -$8.11 |
 Silo Pharma, Inc. SILO | $6M | N/A | — | -$7.57 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.63 | — | |
2024-12-31 FY2024 | — | $-33.33 | — | |
2023-12-31 FY2023 | — | $-208.44 | — | |
2022-12-31 FY2022 | — | $-360.20 | — | |
2021-12-31 FY2021 | — | $-45.82 | — | |
2020-12-31 FY2020 | — | $-2.66 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Calidi Biotherapeutics, Inc. (CLDI) measures how much investors pay for each dollar of the company's trailing earnings. CLDI's current PE ratio of N/A is calculated by dividing its stock price of $0.17 by its TTM earnings per share of -$1.85.
Frequently asked questions
CLDI pe ratio · 6 questionsCLDI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.17 and TTM EPS of -$1.85. Data sourced from Financial Modeling Prep via CLDI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Calidi Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08